Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Think_Bigly
Think_Bigly Jan. 9 at 11:14 PM
$AFMD Roche has a ~$125M+ including trial expense in Affi. I just dont think they walk away from the largest partner deal they've ever created.
1 · Reply
Think_Bigly
Think_Bigly Jan. 9 at 11:08 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jan. 8 at 10:57 PM
$AFMD 70% RMAT Approval in 2024 likely higher in 2025. 'RMAT requests and approvals increased, reaching a 70.7% approval rate in 2024, reflecting improved submission quality and regulatory alignment. These trends highlight the FDA's focus on innovation while maintaining safety and efficacy standards.' https://link.springer.com/article/10.1007/s12247-025-09973-8
0 · Reply
SRT2019
SRT2019 Jan. 7 at 5:03 PM
$AFMD $AFMD One thing we can all agree on is that “ The Diamond 💎” is Acimtamig aka AFM13 that has a 94% Overall Response Rate with a RMAT designation. As a pharmacist who deals with medication on daily basis that is a darn good ORR specially treating one of deadliest cancer Hodgkin Lymphoma. Any potential buyer that could be MD Anderson or Artiva or XOMA Royalty would do love have it. It’s all written on Gilde Healthcare Affimed portfolio. Though this whole insolvency thing is so frustrating because there is science but there is also management/finances who can fail the science.
1 · Reply
Think_Bigly
Think_Bigly Jan. 7 at 2:50 AM
$AFMD $1B Cash Flow in 2030 $497 NPV with $0 for AFM-24 or AFM-28 RMAT-de-risked :: fits acimtamig combo
0 · Reply
Think_Bigly
Think_Bigly Jan. 7 at 2:02 AM
$AFMD
0 · Reply
deathknight
deathknight Jan. 6 at 7:06 PM
$AFMD The very fact that MD Anderson is talking with Bootstrap in it's acquisition attempt is the UNDENIABLE evidence that the asset sale of the subsidiary (affimed gmbh) has been successful and a surplus has been generated after all creditors being paid in full. Otherwise, MD Anderson would have to negotiate with the subsidiary's administrator and Bootstrap would have no place on the table -- they are the secured senior creditor of the parent (affimed N.V.) not the subsidiary and the only way they got paid is through affimed N.V.'s insolvency. Likewise, it is IMPOSSIBLE that MD Anderson is acquiring all affimed GmbH's IP assets as some of us believe. They are buying whatever left after the subsidiary's proceeding -- "substantially all" IP assets of Affimed N.V. (flow back from the subsidiary). They might not care about the difference between affimed gmbh vs affimed N.V. but everyone here should.
1 · Reply
deathknight
deathknight Jan. 6 at 5:06 PM
$AFMD since AI is such a hot-ass, I will just post some of the answers it gave . Certainly Mr right about everything will be able to overthrow those silly answers and confirm that MD Anderson did buy everything with 4.5m.
0 · Reply
Think_Bigly
Think_Bigly Jan. 4 at 11:01 PM
$AFMD is at Peak Stupidity.
0 · Reply
deathknight
deathknight Jan. 4 at 8:01 PM
$AFMD not sure what you guys think. But this essentially tells me what MD Anderson actually bought -- global right to develop and commercialize combo therapies of affimed assets combined with MD Anderson's cord blood NK cells. Just like what I suspected in an earlier post. It's actually a sweet deal since no one other than MD Anderson would buy this (unless a third party acquires the cord blood NK cell license from MD Anderson).
1 · Reply
Latest News on AFMD
No data available.
Think_Bigly
Think_Bigly Jan. 9 at 11:14 PM
$AFMD Roche has a ~$125M+ including trial expense in Affi. I just dont think they walk away from the largest partner deal they've ever created.
1 · Reply
Think_Bigly
Think_Bigly Jan. 9 at 11:08 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Jan. 8 at 10:57 PM
$AFMD 70% RMAT Approval in 2024 likely higher in 2025. 'RMAT requests and approvals increased, reaching a 70.7% approval rate in 2024, reflecting improved submission quality and regulatory alignment. These trends highlight the FDA's focus on innovation while maintaining safety and efficacy standards.' https://link.springer.com/article/10.1007/s12247-025-09973-8
0 · Reply
SRT2019
SRT2019 Jan. 7 at 5:03 PM
$AFMD $AFMD One thing we can all agree on is that “ The Diamond 💎” is Acimtamig aka AFM13 that has a 94% Overall Response Rate with a RMAT designation. As a pharmacist who deals with medication on daily basis that is a darn good ORR specially treating one of deadliest cancer Hodgkin Lymphoma. Any potential buyer that could be MD Anderson or Artiva or XOMA Royalty would do love have it. It’s all written on Gilde Healthcare Affimed portfolio. Though this whole insolvency thing is so frustrating because there is science but there is also management/finances who can fail the science.
1 · Reply
Think_Bigly
Think_Bigly Jan. 7 at 2:50 AM
$AFMD $1B Cash Flow in 2030 $497 NPV with $0 for AFM-24 or AFM-28 RMAT-de-risked :: fits acimtamig combo
0 · Reply
Think_Bigly
Think_Bigly Jan. 7 at 2:02 AM
$AFMD
0 · Reply
deathknight
deathknight Jan. 6 at 7:06 PM
$AFMD The very fact that MD Anderson is talking with Bootstrap in it's acquisition attempt is the UNDENIABLE evidence that the asset sale of the subsidiary (affimed gmbh) has been successful and a surplus has been generated after all creditors being paid in full. Otherwise, MD Anderson would have to negotiate with the subsidiary's administrator and Bootstrap would have no place on the table -- they are the secured senior creditor of the parent (affimed N.V.) not the subsidiary and the only way they got paid is through affimed N.V.'s insolvency. Likewise, it is IMPOSSIBLE that MD Anderson is acquiring all affimed GmbH's IP assets as some of us believe. They are buying whatever left after the subsidiary's proceeding -- "substantially all" IP assets of Affimed N.V. (flow back from the subsidiary). They might not care about the difference between affimed gmbh vs affimed N.V. but everyone here should.
1 · Reply
deathknight
deathknight Jan. 6 at 5:06 PM
$AFMD since AI is such a hot-ass, I will just post some of the answers it gave . Certainly Mr right about everything will be able to overthrow those silly answers and confirm that MD Anderson did buy everything with 4.5m.
0 · Reply
Think_Bigly
Think_Bigly Jan. 4 at 11:01 PM
$AFMD is at Peak Stupidity.
0 · Reply
deathknight
deathknight Jan. 4 at 8:01 PM
$AFMD not sure what you guys think. But this essentially tells me what MD Anderson actually bought -- global right to develop and commercialize combo therapies of affimed assets combined with MD Anderson's cord blood NK cells. Just like what I suspected in an earlier post. It's actually a sweet deal since no one other than MD Anderson would buy this (unless a third party acquires the cord blood NK cell license from MD Anderson).
1 · Reply
deathknight
deathknight Jan. 4 at 4:21 AM
$AFMD last post for this matter: if the board agenda is real and authentic, considering the poor language it involves, it actually could mean that MD Anderson purchased the right to globally commercialize and develop therapeutics for affimed GmbH's assets combo with MD Anderson's cord blood NK cell products. Per existing agreement, affimed gmbh holds this right (https://www.mdanderson.org/newsroom/md-anderson-and-affi.h00-159142089.html)and it makes a lot sense for MD Anderson to acquire it with those terms (small upfront + fairly big future loyalties). The title of that section (item 60) does say " acquisition of certain Affimed GmbH assets for mission-related purposes".
1 · Reply
deathknight
deathknight Jan. 4 at 3:48 AM
$AFMD @caradhras36 how did you get to know the UT board agenda? The file's root folder is not accessible to general public (and I doubt even average UT folks have access) and the only way to access the file is know the exact path and file name -- this is not some information that average Joe (like myself) on stocktwits can get hands on. Are you associated with UT system or more specifically, MD Anderson?
2 · Reply
deathknight
deathknight Jan. 4 at 3:08 AM
$AFMD just realized that if the sale of affimed gmbh netted only 4.5m and insufficient to pay outstanding debt, then the parent (affimed N.V.) even as a secures creditor will get less than 4.5m which is insufficient to cover its loan provided by Bootstrap (about 9.4m per the most recent 6k). Therefore the administrator of the parent company would be required by the law to claim insufficient assets at the opening of the formal proceeding -- which wasn't the case. I think it's safe to assume the cash generated from selling the subsidiary was more than 9.4m based on this fact. Let's see what will happen in the end -- it's not too far down the line.
0 · Reply
deathknight
deathknight Jan. 4 at 2:22 AM
$AFMD two more things: 1. if MD Anderson did acquire everything for a mere 4.5m, then there is 100% certainty no money will be left for the parent (affimed N.V.) and its own insolvency proceeding will be dismissed since it has no money to even go through the proceeding. 2. the so-called main creditor (bootstrap) is not even named on the creditors' committee -- it has no claim or whatsoever to "pick" MD Anderson as the final candidate -- especially so if the net sale is insufficient to pay all outstanding creditors. This "board agenda" seems to come from an authentic address but it's not a legally bonding document and without any security measure -- anyone can download and edit it. If someone managed to be able to upload/overwrite the original file -- they can make whatever they want into the "agenda".
0 · Reply
deathknight
deathknight Jan. 4 at 12:52 AM
$AFMD what we have here? A nobody-knows true or not internal document from UT system and one of its appendix really decided the fate of everything? In insolvency proceedings, creditors don't "own" any of the debtor's assets-- that languages alone annihilated every words in that "board agenda". The debtor (affimed gmbh) was and is the ower of all its assets, the court protects them from being taken by the creditors -- this exactly is the reason of any company ever wants to go through insolvency. Also does anyone here really believe companies like Artiva can't even beat that measly 4.5m? They have a RMAT designation with the AFM13 with their cells. Dont be absurd.
1 · Reply
Think_Bigly
Think_Bigly Jan. 4 at 12:50 AM
$AFMD Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
Think_Bigly
Think_Bigly Jan. 4 at 12:48 AM
$AFMD NPV of $1 Billion Cash Flow in 2028 :: AFM13/AlloNK - ARTV 33%. AFM24 and AFM28 are not included: $0 value. Clinical-stage biotech valuations typically use higher discount rates Lower rates (e.g., 12%) are reserved for more de-risked late-stage or post-RMAT assets.
0 · Reply
Think_Bigly
Think_Bigly Jan. 3 at 11:54 PM
$AFMD Grok refers to AFMD as a RMAT-de-risked platform. DE-Risked.. meaning approvals will follow.
0 · Reply
DrPump_
DrPump_ Jan. 3 at 4:45 PM
$AFMD Katy Rezvani - a fascinating and brilliant woman of science - humiliated the whole Affimed management team (Adi and his crew), buying them out for peanuts.
2 · Reply
Hodl707
Hodl707 Jan. 3 at 2:15 PM
$AFMD Yes, it’s fake. After thorough checks (including direct access to the UT System Board of Regents agendas and MD Anderson sources), there is no evidence of any acquisition of Affimed’s assets by MD Anderson Cancer Center (or “U.T.M.D. Anderson”) in the November 19-20, 2025 meeting or any other date.
2 · Reply
Omarhabibeh
Omarhabibeh Jan. 3 at 11:51 AM
$AFMD Our only hope is that AFMD N.V. (which means "us, the shareholders") will be eligible for some royalties. These royalties could reach hundreds of millions after commercialization. This could attract investors to buy shares from the market. I'm daydreaming again. 😥
0 · Reply
DrPump_
DrPump_ Jan. 3 at 9:11 AM
$AFMD further confirmation that science was great but management has been terrible.
1 · Reply